Ionica Sciences, Ithaca, NY, USA.
Department of Chemistry, The City College of New York, New York, NY, USA.
Nanomedicine. 2022 Apr;41:102528. doi: 10.1016/j.nano.2022.102528. Epub 2022 Jan 30.
Lyme disease is the fastest growing vector-borne disease in the United States. However, current testing modalities are ill suited to detection of Lyme disease, leading to the diagnosis of many cases after treatment is effective. We present an improved, direct method Lyme disease diagnosis, where the Lyme specific biomarker Outer Surface Protein A (OspA) in clinical serum samples is identified using a diagnostic platform combining surface enhanced Raman scattering (SERS) and aptamers. Employing orthogonal projections to latent structures discriminant analysis, the system accurately identified 91% of serum samples from Lyme patients, and 96% of serum samples from symptomatic controls. In addition, the OspA limit-of-detection, determined to be 1 × 10 ng/mL, is greater than four orders of magnitude lower than that found in serum samples from early Lyme disease patients. The application of this platform to detect this difficult-to-diagnose disease suggests its potential for detecting other diseases that present similar difficulties.
莱姆病是美国增长最快的虫媒传染病。然而，目前的检测方法并不适合检测莱姆病，导致许多病例在治疗有效后才被诊断出来。我们提出了一种改进的、直接的莱姆病诊断方法，该方法使用结合表面增强拉曼散射（SERS）和适体的诊断平台，鉴定临床血清样本中的莱姆病特异性生物标志物外表面蛋白 A（OspA）。采用正交投影到潜在结构判别分析，该系统准确地识别了 91%的莱姆病患者的血清样本，以及 96%的有症状对照者的血清样本。此外，OspA 的检测限为 1×10ng/mL，比早期莱姆病患者血清样本中的检测限低四个数量级以上。该平台在检测这种难以诊断的疾病中的应用表明，它有可能用于检测其他具有类似诊断困难的疾病。
